Management of asymptomatic rise in prostatic-specific antigen in patients with prostate cancer

Current Oncology Reports

Volumn 8, Issue 3, 2006, Pages 213-220

  Mohile, Supriya G ^a   Petrylak, Daniel P ^b  

^a New York Presbyterian Hospital Columbia University Medical Center   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; CAPROMAB PENDETIDE IN 111; ESTROGEN; FINASTERIDE; FLUTAMIDE; GONADORELIN AGONIST; PLACEBO; PROSTATE SPECIFIC ANTIGEN;

BIOCHEMISTRY; BONE METASTASIS; BONE SCINTISCANNING; BRACHYTHERAPY; BREAST TENDERNESS; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CRYOTHERAPY; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FOLLOW UP; GASTROINTESTINAL DISEASE; GLEASON SCORE; GYNECOMASTIA; HUMAN; IMAGING SYSTEM; IMPOTENCE; LIBIDO DISORDER; LYMPH NODE METASTASIS; MALE; MICROMETASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; ORCHIECTOMY; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SALVAGE THERAPY; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SYMPTOM; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT FAILURE; UROGENITAL SCINTISCANNING;

HUMANS; MALE; MEDICAL ONCOLOGY; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SALVAGE THERAPY;

EID: 33646251394     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-006-0022-8     Document Type: Review

References (61)

1. Jemal A, Murray T, Ward E, et al.: Cancer statistics, 2005. CA Cancer J Clin 2005, 55:10-30.
2. Moul JW. Variables in predicting survival based on treating "PSA-only" relapse. Urol Oncol 2003, 21:292-304.
3. Djavan B, Moul JW, Zlotta A, et al.: PSA progression following radical prostatectomy and radiation therapy: new standards in the new millennium. Eur Urol 2003, 43:12-27.
4. Ward JF, Moul JW: Biochemical recurrence after definitive prostate cancer therapy. Part II: treatment strategies for biochemical recurrence of prostate cancer. Curr Opin Urol 2005, 15:187-195.
5. D'Amico AV, Moul J, Carroll PR, et al.: Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 2003, 21:2163-2172.
6. Ravery V: The significance of recurrent PSA after radical prostatectomy: benign versus malignant sources. Semin Urol Oncol 1999, 17:127-129.
7. Partin AW, Pearson JD, Landis PK, et al.: Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 1994, 43:649-659.
8. Lange PH, Ercole CJ, Lightner DJ, et al.: The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol 1989, 141:873-879.
9. Amling CL, Bergstralh EJ, Blute ML, et al.: Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol 2001, 165:1146-1151.
10. Djavan B, Waldert M, Ghawidel C, et al.: Benign prostatic hyperplasia progression and its impact on treatment. Curr Opin Urol 2004, 14:45-50.
11. Stephenson AJ, Eastham JA: Role of salvage radical prostatectomy for recurrent prostate cancer after radiation therapy. J Clin Oncol 2005, 23:8198-8203.
12. Rosser CJ, Kuban DA, Levy LB, et al.: Prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancer. J Urol 2002, 168:2001-2005.
13. Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 1997, 37:1035-1041.
14. Horwitz EM, Uzzo RG, Hanlon AL, et al.: Modifying the American Society for Therapeutic Radiology and Oncology definition of biochemical failure to minimize the influence of backdating in patients with prostate cancer treated with 3-dimensional conformal radiation therapy alone. J Urol 2003, 169:2153-2157; discussion 2157-2159.
15. Kuban DA, Thames HD, Shipley WU: Defining recurrence after radiation for prostate cancer. J Urol 2005, 173:1871-1878.
16. Pound CR, Partin AW, Eisenberger MA, et al.: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999, 281:1591-1597.
17. Jhaveri FM, Zippe CD, Klein EA, et al.: Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10-year results. Urology 1999, 54:884-890.
18. D'Amico AV, Moul JW, Carroll PR, et al.: Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003, 95:1376-1383.
19. Patel DA, Presti JC, Jr., McNeal JE, et al.: Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy. J Clin Oncol 2005,23:6157-6162.
20. Patel A, Dorey F, Franklin J, et al.: Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol 1997, 158:1441-1445.
21. D'Amico AV, Cote K, Loffredo M, et al.: Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 2002, 20:4567-4573.
22. Cher ML, Bianco FJ, Jr., Lam JS, et al.: Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol 1998, 160:1387-1391.
23. Kane CJ, Amling CL, Johnstone PA, et al.: Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology 2003, 61:607-611.
24. Okotie OT, Aronson WJ, Wieder JA, et al.: Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. J Urol 2004, 171:2260-2264.
25. Quintana JC, Blend MJ: The dual-isotope ProstaScint imaging procedure: clinical experience and staging results in 145 patients. Clin Nucl Med 2000, 25:33-40.
26. Kahn D, Williams RD, Manyak MJ, et al.: 111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group. J Urol 1998, 159:2041-2046; discussion 2046-2047.
27. Levesque PE, Nieh PT, Zinman LN, et al.: Radiolabeled monoclonal antibody indium 111-labeled CYT-356 localizes extraprostatic recurrent carcinoma after prostatectomy. Urology 1998, 51:978-984.
28. Raj GV, Partin AW, Polascik TJ: Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. Cancer 2002, 94:987-996.
29. Hinkle GH, Burgers JK, Neal CE, et al.: Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide. Cancer 1998, 83:739-747.
30. Kahn D, Williams RD, Haseman MK, et al.: Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectorny. J Clin Oncol 1998, 16:284-289.
31. Thomas CT, Bradshaw PT, Pollock BH, et al.: Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. J Clin Oncol 2003, 21:1715-1721.
32. Ward JF, Zincke H, Bergstralh EJ, et al.: Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy. J Urol 2004, 172:2244-2248.
33. Stephenson AJ, Shariat SF, Zelefsky MJ, et al.: Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 2004,291:1325-1332.
34. Garg MK, Tekyi-Mensah S, Bolton S, et al.: Impact of postprostatectomy prostate-specific antigen nadir on outcomes following salvage radiotherapy. Urology 1998, 51:998-1002.
35. MacDonald OK, Schild SE, Vora S, et al.: Salvage radiotherapy for men with isolated rising PSA or locally palpable recurrence after radical prostatectomy: do outcomes differ?. Urology 2004, 64:760-764.
36. Cadeddu JA, Partin AW, DeWeese TL, et al.: Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J Urol 1998, 159:173-177; discussion 177-178.
37. Bianco FJ, Jr., Scardino PT, Stephenson AJ, et al.: Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy. Int J Radiat Oncol Biol Phys 2005, 62:448-453.
38. Gheiler EL, Tefilli MV, Tiguert R, et al.: Predictors for maximal outcome in patients undergoing salvage surgery for radiorecurrent prostate cancer. Urology 1998, 51:789-795.
39. Amling CL, Lerner SE, Martin SK, et al.: Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer. J Urol 1999, 161:857-862; discussion 862-853.
40. Garzotto M, Wajsman Z: Androgen deprivation with salvage surgery for radiorecurrent prostate cancer: results at 5-year followup. J Urol 1998, 159:950-954; discussion 954-955.
41. Izawa JI, Ajam K, McGuire E, et al.: Major surgery to manage definitively severe complications of salvage cryotherapy for prostate cancer. J Urol 2000, 164:1978-1981.
42. Ghafar MA, Johnson CW, De La Taille A, et al.: Salvage cryotherapy using an argon based system for locally recurrent prostate cancer after radiation therapy: the Columbia experience. J Urol 2001, 166:1333-1337; discussion 1337-1338.
43. Han KR, Cohen JK, Miller RJ, et al.: Treatment of organ confined prostate cancer with third generation cryosurgery: preliminary multicenter experience. J Urol 2003, 170:1126-1130.
44. Grado GL, Collins JM, Kriegshauser JS, et al.: Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology 1999, 53:2-10.
45. Sylvester J, Grimm P, Blasco J, et al.: The role of androgen ablation in patients with biochemical or local failure after definitive radiation therapy: a survey of practice patterns of urologists and radiation oncologists in the United States. Urology 2001, 58:65-70.
46. Duchesne GM, Millar JL, Moraga V, et al.: What to do for prostate cancer patients with a rising PSA? - A survey of Australian practice. Int J Radiat Oncol Biol Phy 2003, 55:986-991.
47. Mehta SS, Lubeck DP, Sadetsky N, et al.: Patterns of secondary cancer treatment for biochemical failure following radical prostatectomy: data from CaPSURE. J Urol 2004, 171:215-219.
48. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet 2000, 355:1491-1498.
49. Caubet JF, Tosteson TD, Dong EW, et al.: Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology 1997, 49:71-78.
50. Bennett CL, Tosteson TD, Schmitt B, et al.: Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: a meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide. Prostate Cancer Prostatic Dis 1999, 2:4-8.
51. Bertagna C, De Gery A, Hucher M, et al.: Efficacy of the combination of nilutamide plus orchiectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomized double-blind trials (1056 patients). Br J Urol 1994, 73:396-402.
52. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol 1997, 79:235-246.
53. Messing EM, Manola J, Sarosdy M, et al.: Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999, 341:1781-1788.
54. Moul JW, Wu H, Sun L, et al.: Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 2004, 171:1141-1147.
55. Seidenfeld J, Samson DJ, Hasselblad V, et al.: Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000, 132:566-577.
56. Denis LJ, Keuppens F, Smith PH, et al.: Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center. Eur Urol 1998, 33:144-151.
57. Bales GT, Chodak GW: A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology 1996, 47:38-43; discussion 48-53.
58. Iversen P: Bicalutamide monotherapy for early stage prostate cancer: an update. J Urol 2003, 170:S48-S52; discussion S52-S44.
59. Wirth MP, See WA, McLeod DG, et al.: Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J Urol 2004, 172:1865-1870.
60. Barqawi AB, Moul JW, Ziada A, et al.: Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy. Urology 2003, 62:872-876.
61. Oh WK, Manola J, Bittmann L, et al.: Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up. Urology 2003, 62:99-104.